María L. Amador - Concepedia

Author

María L. Amador

Also Known As

M Luz Amador Muñoz, M MUNOZ, M. Amador, M. L. Amador, M. Munoz, M.-L. Amador, M.L Amador, M.L. Amador, Maria Amador, Maria L Amador

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine Hospital Universitario 12 De Octubre University of Southern California

About

María L. Amador is an author at Johns Hopkins University specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	321
2	Biology	3	3	43
3	Natural Sciences	2	2	33
4	Engineering	1	1	10
5	Biochemistry	1	1	10

María L. Amador

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer Belén Rubio‐Viqueira, Antonio Jimeno, George Cusatis, Clinical Cancer Research	2006	411
An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors María L. Amador, Darin Oppenheimer, Sofía Perea, Cancer Research	2004	242
A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) Luis Paz‐Ares, J. M. Sanchez, A. García, Journal of Clinical Oncology Advanced NsclcMedicineTyrosine KinasePharmacologyHigh Response Rate	2006	162
Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents Antonio Jimeno, Belén Rubio‐Viqueira, María L. Amador, Cancer Research	2005	105
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy Ricardo Hitt, Eva Ciruelos, María L. Amador, European Journal of Cancer Advanced HeadMedicinePrognostic ValuePathologyHead And Neck Cancer	2004	63
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy Eva Barragán, Pau Montesinos, Mireia Camós, Haematologica	2011	63
Physiological and biochemical parameters controlling waterlogging stress tolerance in <b><i>Prunus</i></b> before and after drainage María L. Amador, S. Sancho, Beatriz Bielsa, Physiologia Plantarum	2012	58
Impact of the COVID-19 pandemic on the care of cancer patients in Spain María L. Amador, Xavier Matías‐Guiu, Gemma Sancho, ESMO Open	2021	52
ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer Giuseppe Curigliano, Daniele Santini, Linda Sharp, ESMO Open	2024	43
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Ricardo Hitt, María L. Amador, Miguel Quintela-Fandiño, Cancer	2005	42

Page 1